Kfar-Sava, Israel Clinical Trials

A listing of Kfar-Sava, Israel clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 111 clinical trials
featured
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

www.MyelofibrosisResearch.com This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.

Tel Aviv Sourasky Medical Center /ID# 230311
 (9.7 away) Contact site
  • 251 views
  • 29 Apr, 2021
  • +134 other locations
featured
A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations

A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations

urinary tract cancer
Research Center
 (9.8 away) Contact site
  • 1062 views
  • 08 Dec, 2020
  • +61 other locations
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

The purpose of this study is to evaluate the objective response rate (complete response [CR]+ partial response [PR]) of the selected dose regimen in participants with metastatic or surgically unresectable urothelial cancers that harbor specific FGFR genomic alterations.

renal function
dose regimen
measurable disease
erdafitinib
adjuvant chemotherapy
Rabin Medical Center - Bellins
 (6.6 away) Contact site
  • 40 views
  • 29 May, 2021
  • +150 other locations
Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence

The primary objective of the trial is to investigate if nivolumab plus ipilimumab given as adjuvant treatment improve disease free survival (DFS) in patients with stage Ib-IVa gastric and esophagogastric junction adenocarcinoma and high risk of recurrence (defined by ypN1-3 and/or R1 status) following neoadjuvant chemotherapy and resection. Other study …

Rabbin Medical Centre - Tel Aviv
 (9.7 away) Contact site
  • 33 views
  • 10 Feb, 2021
  • +24 other locations
Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

To evaluate the safety and efficacy of Zimura (complement factor C5 inhibitor) compared to Sham in subjects with autosomal recessive Stargardt disease 1 (STGD1).

Rabin Medical Center, Beilinson campus
 (6.6 away) Contact site
  • 114 views
  • 13 May, 2021
  • +39 other locations
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of care therapy; and 2) are positive for homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD).

Chaim Sheba Medical Center ( Site 0803)
 (9.0 away) Contact site
  • 135 views
  • 16 Jun, 2021
  • +146 other locations
A Safety Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis

This is a phase 2 randomized, multi-center, double-blind, vehicle controlled, 90 day, safety, efficacy, and systemic exposure study followed by a 90 day open-label extension of trifarotene cream in adults and adolescents with autosomal recessive ichthyosis with lamellar scale.

Tel Aviv Sourasky MC
 (9.7 away) Contact site
  • 101 views
  • 12 Mar, 2021
  • +34 other locations
KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-na ve Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) PLUS chemotherapy in combination with vibostolimab (MK-7684) or MK-5890 in treatment-nave participants with advanced squamous or non-squamous NSCLC. This study is one of three pembrolizumab substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01).

cancer chemotherapy
pembrolizumab
targeted therapy
paclitaxel
stage iv non-small cell lung cancer
Rabin Medical Center ( Site 0074)
 (6.6 away) Contact site
  • 2 views
  • 26 Apr, 2021
  • +24 other locations
Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)

This study will evaluate the safety, efficacy, and pharmacokinetics of posaconazole (POS) intravenous (IV) and oral formulations in pediatric participants 2 to <18 years of age with invasive aspergillosis (IA).

cancer
posaconazole
fungal infection
Chaim Sheba Medical Center ( Site 1126)
 (9.6 away) Contact site
  • 0 views
  • 15 May, 2021
  • +24 other locations
Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis

In this study researchers want to learn about the safety of drug Osocimab at low and high doses in adult participants with kidney disease undergoing regular dialysis (a procedure that uses a machine to get rid of toxins and extra fluids in the blood). Patients with kidney disease undergoing regular …

Clalit Health Services Rabin Medical Center-Beilinson Campus
 (6.6 away) Contact site
  • 20 views
  • 28 May, 2021
  • +215 other locations